Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Fineline Cube Jun 4, 2026
Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Fineline Cube Jun 3, 2026
Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Fineline Cube Jun 3, 2026
Company Deals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Fineline Cube Jun 2, 2026
Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Fineline Cube Jun 2, 2026
Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

Fineline Cube Jun 4, 2026
Company Drug

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Fineline Cube Jun 4, 2026
Company Drug

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Fineline Cube Jun 3, 2026
Company Deals

Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution

Fineline Cube Sep 15, 2022

China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with...

Company Deals

Suzhou Jade Biomedical Secures USD 10 Million Series B Financing

Fineline Cube Sep 15, 2022

China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B...

Company Deals

Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding

Fineline Cube Sep 15, 2022

Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...

Company Deals

Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center

Fineline Cube Sep 15, 2022

China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...

Company Deals

Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion

Fineline Cube Sep 15, 2022

Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...

Company Drug

Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance

Fineline Cube Sep 15, 2022

China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...

Company Deals

Bide Pharmatech Set for IPO on Shanghai’s STAR Market

Fineline Cube Sep 15, 2022

Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...

Drug Policy / Regulatory

NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Sep 15, 2022

The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...

Company Drug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

Fineline Cube Sep 15, 2022

Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...

Policy / Regulatory

Guangdong Launches Free HPV Vaccination Program for School-aged Girls

Fineline Cube Sep 15, 2022

Guangdong province has rolled out a free HPV vaccination program this month, aimed at improving...

Company Drug

Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis

Fineline Cube Sep 15, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...

Policy / Regulatory

Hubei Province Proposes National TCM Patent Medicine Procurement Alliance

Fineline Cube Sep 15, 2022

The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...

Company Drug

Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study

Fineline Cube Sep 15, 2022

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...

Company Drug

CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment

Fineline Cube Sep 15, 2022

The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...

Company Drug

Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study

Fineline Cube Sep 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Drug

I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial

Fineline Cube Sep 14, 2022

China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...

Company Drug

Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...

Company Drug

Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod

Fineline Cube Sep 14, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...

Company Deals

Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital

Fineline Cube Sep 14, 2022

China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions”...

Company Policy / Regulatory

NMPA Issues Guidelines on Medical Device Grading Administration

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) has released a set of Guiding Opinions on “Medical...

Posts pagination

1 … 636 637 638 … 677

Recent updates

  • Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke
  • Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%
  • FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing
  • China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030
  • Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Company

Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%

Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

Policy / Regulatory

China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.